Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Temasek Chief Investment Officer warns: AI trading reversal is the biggest market risk, turbulence may occur in 2027

Temasek Chief Investment Officer warns: AI trading reversal is the biggest market risk, turbulence may occur in 2027

智通财经智通财经2026/10/07 10:09
Show original

Temasek's CIO stated that AI-driven trading reversals represent the greatest market risk, with possible turbulence in 2027; however, he remains optimistic in the long term and plans to raise public AI exposure to 70%—75%.

Golden Ten Data APP has learned that Singaporean state-owned investment giant Temasek stated that a reversal in artificial intelligence trading is the greatest risk facing the market.

Temasek Chief Investment Officer Rohit Sipahimalani said, "We don’t see this as an imminent issue, but could there be volatility in 2027? Yes, it’s possible."

Sipahimalani said that even if US Treasury yields rise sharply, AI remains one of the key factors supporting US stocks near record highs, noting that large companies related to this technology are delivering strong earnings performance.

He pointed out that despite rising borrowing costs, the S&P 500 Index is still hovering near record highs, supported by "AI and the earnings momentum surrounding the leading players."

However, the strength of the index masks underlying weakness. Sipahimalani noted that about half of the components in the Russell 3000 Index have fallen at least 20% from their June peaks, highlighting how much the market’s resilience relies on a handful of winners.

He said a reversal in AI trading could be triggered by multiple factors, including safety concerns that lead to regulatory tightening or signs that clients’ investments in this technology are not generating sufficient returns.

Nevertheless, Temasek remains long-term bullish on artificial intelligence and continues to increase its investments in this field. Sipahimalani said about half of the company’s current AI exposure is allocated to publicly traded assets, ideally aiming to raise this proportion to around 70% to 75%.

Compared to private assets, which are harder to exit quickly, this will give Temasek greater flexibility to adjust investments as the industry evolves.

"One thing we recognize is that AI is an extremely fast-moving environment where things can easily change, and you have to be able to pivot," he said.

Temasek has invested in private AI model developers such as OpenAI and Anthropic, but "the scale of exposure in these areas is different from some areas where we have greater flexibility," said Sipahimalani.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court

October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)

路透社•2026/10/07 13:31

BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises

On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.

路透社•2026/10/07 13:27

Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.

Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.

智通财经•2026/10/07 13:18